ClinicalTrials.gg
Not yet recruitingNCT07926776BRIDGE-ADHDUpdated Nov 9, 2026

Supporting Families of School-Aged Children With ADHD: A Dual-Generation Therapy Approach Through the BRIDGE Program

An interventional study of BRIDGE-ADHD in ADHD, Maternal Mental Health and Dialectical Behavior Therapy, sponsored by University of Manitoba. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Manitoba · Not applicable, Interventional, and Treatment

Updated Nov 9, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The present research study will evaluate the feasibility and preliminary efficacy of the adapted Building Regulation in Dual Generations program for families of children (8-12 years old) with Attention-Deficit/Hyperactivity Disorder, creating the BRIDGE-ADHD program. The BRIDGE-ADHD program combines 10 weekly online psycho-education sessions with knowledge about ADHD and relevant parenting skills training videos to improve maternal wellbeing and parenting practices, thus supporting children's own psychological wellbeing through an intergenerational approach. This study will specifically evaluate whether the BRIDGE-ADHD program is able to reduce mothers' psychological distress (e.g., depression, anxiety, parenting stress) and simultaneously reduce their children's attention and/or behaviour problems.

Read the detailed description

Families of children with attention-deficit/hyperactivity disorder (ADHD) often experience elevated parenting stress. Maternal psychological distress (e.g., symptoms of depression and anxiety) is associated with harsher parenting practices that may increase children's risk for both externalizing and internalizing behaviour problems, including ADHD symptoms such as hyperactivity, impulsivity, and inattention. ADHD is in turn associated with deficits in self-regulation and executive functioning, which tend to result in social and academic difficulties that negatively impact the lives of children and families.

Supporting parents through effective parenting strategies is a key modifiable factor that can reduce child behavioural difficulties. Improving parent mental health by reducing parenting stress through skills-based parenting and psychoeducation may reduce parental distress and improve family functioning.

The Building Regulation in Dual Generations program (BRIDGE) for ADHD program is designed to provide mothers with mental health support and parenting skills that promote more effective management of their child's ADHD symptoms and, ultimately, reduce attention and behaviour problems through improvements in self-regulation. BRIDGE-ADHD is an adapted 10 week program that aims to support intergenerational emotion regulation and positive parenting strategies. The program combines dialectical behaviour therapy (DBT) skills with parenting-focused psychoeducational content. Each week, participants will attend a 1.5 hour synchronous online group session led by a licensed clinical psychologist, co facilitated by clinical psychology graduate students under supervision, and a peer parent coach who has previously participated in the BRIDGE program.

This study will use a non-randomized, parallel-assignment feasibility pilot design to evaluate the feasibility and potential efficacy of BRIDGE-ADHD in addressing parenting stress and children's attentional and behavioural problems. We will recruit thirty parent-child dyads (15 intervention participants and 15 normative controls). Participants in the intervention group will complete the 10 week online BRIDGE-ADHD program and in person assessments at two time points: pre intervention (week 0-1; T0) and post intervention (week 10; T1). The normative control group will complete the same in person assessments without participating in the intervention. The primary aim is to examine the feasibility and acceptability of BRIDGE-ADHD and its impact on maternal mental health and children's social-emotional development.

Secondary aims are to evaluate the program's efficacy in reducing parenting stress and decreasing harsh parenting tendencies. Exploratory aims include examining differences or changes in sleep quality, mental well-being, relationships, and child academic achievement before and after participation in BRIDGE-ADHD.

02

Conditions studied

  • ADHD
  • Maternal Mental Health
  • Dialectical Behavior Therapy
  • Parenting Intervention
  • Children

Keywords

  • ADHD
  • Parenting
  • online therapy
  • DBT skills
  • children
03

In context

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 296 are open to participants now.

This study's planned enrollment of 30 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.

Browse Attention Deficit Disorder with Hyperactivity studies →

Lead sponsor

University of Manitoba is the lead sponsor of 555 studies on the registry; 89 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mothers must be 18 years old or older with both current and elevated symptoms of depression (T-score > 5 on the PHQ-9).

    • Mothers must have a child between the ages of 8 and 12 years old.
    • Both mothers and children must currently live in Manitoba.
    • Mothers must self-report that their child has a diagnosis of ADHD. This will be confirmed by having mothers complete the CBCL (T-score > 65) and through intake interviews with clinicians.
    • Both mothers and children must speak fluent English.
    • Mothers must have neither attempted suicide within the past year nor self-harmed resulting in an injury that either did or should have received medical attention within the past 6 months.

Exclusion criteria

Exclusion Criteria:

  • not meeting the listed criteria above
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    BRIDGE-ADHD

    The group that will receive the BRIDGE-ADHD program

    Behavioral: BRIDGE-ADHD

  • No intervention
    Normative Control

    This is a normative control group who will not be receiving any intervention.

Interventions

  • BehavioralBRIDGE-ADHD

    The BRIDGE-ADHD program is a 10-week program that combines online psychoeducation sessions with parenting manual handouts and parenting skills training videos to improve maternal wellbeing and promote positive parenting practices tailored to the needs of families of children with ADHD. The BRIDGE-ADHD program content is largely based on mindfulness and dialectical behaviour therapy (DBT) skills, including emotion regulation, distress tolerance, and other related skills. The program will also include psycho-education on ADHD and parenting skills

06

What researchers measure

Primary outcomes

  1. Changes in child mental health symptoms following BRIDGE-ADHD intervention

    Changes in child mental health symptoms will be measured using the Child Behavior Checklist (CBCL) for ages 6 to 18. The CBCL is a 100-item parent-report questionnaire with a range of scores from 0 to 200, measuring child functioning across externalizing and internalizing symptoms. All raw scores are converted into T-scores across all domains tested to have a standardized outcome. Higher T-scores indicate greater symptom severity. We will use the CBCL to assess a) total behaviour problems, b) ADHD subscale scores, c) internalizing behaviours, and d) externalizing behaviours. These subscale scores will collectively be investigated as child mental health symptoms.

    Time frame: This measure will be administered at baseline, (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention which will occur between weeks 11-12 (noted as T1).

  2. Changes in maternal depressive symptoms

    Depressive symptoms will be measured using the Patient Health Questionnaire 9-Item (PHQ-9). The PHQ-9 is a 9-item self-report questionnaire with a range of scores from 0 to 27. Higher scores indicate greater symptom severity.

    Time frame: This measure will be administered at baseline, which is considered week 0-1 (noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention taking place at weeks 11-12 ( noted as T1).

  3. Maternal ratings of program acceptability

    Maternal ratings of program acceptability will be collected using an open-ended program acceptability questionnaire developed by the research team. Participants will rate how important various components of the program were to them and will be asked to respond to open-ended questions regarding their experience in the program.

    Time frame: This measure will be administered after the 10 week of BRIDGE intervention, post-intervention (noted as T1) expected to take place sometime between weeks 11-12.

  4. Recruitment Feasibility Metrics

    The feasibility of the BRIDGE-ADHD program will be evaluated using a range of implementation metrics. Recruitment feasibility will be assessed by examining eligibility rates, enrollment rates, and the time required to recruit the target sample. All of these measures will be presented in rates allowing for common measurement across domains.

    Time frame: These will be measured from beginning of the study recruitment till the end of the pilot trial. This time frame can be up to 1 year.

  5. Data Collection Feasibility

    The feasibility of the BRIDGE-ADHD program will be evaluated using a range of implementation metrics. Data collection feasibility will be determined by the proportion of participants completing baseline and post-intervention assessments, rates of missing data, and the time required to complete study measures.

    Time frame: These will be measured from beginning of the study recruitment till the end of the pilot trial. This time frame can be up to 1 year.

  6. Program Implementation Outcomes

    Program implementation outcomes, including session attendance, reasons for missed sessions or withdrawal, scheduling challenges, technological issues and facilitator reflections on program delivery

    Time frame: These will be measured from beginning of the study recruitment till the end of the pilot trial. This time frame can be up to 1 year.

  7. Program Retention Measure

    Retention and adherence will be measured by the proportion of participants who complete the program, attendance rates across the 10 sessions, and watching home videos, where applicable.

    Time frame: These will be measured from beginning of the study recruitment till the end of the pilot trial. This time frame can be up to 1 year.

Secondary outcomes

  1. Changes in parent ratings of child behaviours

    Changes in parent ratings of child behaviours will be measured using the Behaviour Assessment System for Children - Third Edition (BASC-3). The BASC-3 is a parent-report questionnaire measuring externalizing and internalizing problems, attention problems, school problems, as well as adaptive strengths like social skills and study skills. All raw scores are converted into T-scores across all domains tested to have a standardized outcome. Higher T-scores on problem factors indicate more severe problems. Higher T-scores on strengths indicate more of those strengths. We will be specifically looking at broader subscale scores to identify if there has been any change in child behaviours.

    Time frame: This measure will be administered at baseline, (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention which will occur between weeks 11-12 (noted as T1).

  2. Changes in Parenting stress

    Parenting stress will be measured using the Parenting Stress Index Short Form (PSI-SF). The PSI-SF is a self-report questionnaire requiring respondents to answer questions regarding their overall experience of parenting stress using a 5-point Likert with a range of scores range from 36 to 180. All raw scores are converted into T-scores across all domains tested to have a standardized outcome. Higher T-scores indicate higher levels of parenting stress. Changes in total parenting stress score will be measured.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  3. Changes in difficulties with maternal emotion regulation

    Changes in difficulties with emotion regulation will be measured using the Difficulties in Emotion Regulation 36-Item Scale (DERS-36). The DERS-36 is a self-report questionnaire assessing emotion dysregulation across 6 dimensions, including nonacceptance of emotions, difficulties with goal-directed behaviour, impulse control, lack of emotional awareness, limited access to regulation strategies, and lack of emotional clarity. Respondents rate often each statement describes them on a 5-point Likert scale with higher scores indicating greater difficulties. All raw scores are converted into T-scores across all domains tested to have a standardized outcome. Total scores range from 36 to 180 with higher score indicating greater overall difficulties with emotion regulation. Changes in total emotion regulation T-score will be measured.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  4. Changes in maternal feelings of anger

    Changes in anger will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anger subscale. The PROMIS Anger subscale contains 5 items with a range of scores from 5 to 25. Higher scores indicate higher levels of anger.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  5. Changes in maternal sleep problems

    Changes in maternal sleep disturbances will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance subscale short form. The subscale contains 8 items with a range of scores from 8 to 40. Higher scores indicate greater sleep disturbance severity.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  6. Changes in children's sleep habits

    Changes in children's sleep habits will be measured using the Children's Sleep Habits Questionnaire (CSHQ). The CSHQ is a 45-item parent-report questionnaire assessing common sleep problems in children aged 4 to 12, including bedtime resistance and night waking. Higher scores indicate more severe sleep problems with scores above 41 suggesting clinical concerns.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  7. Changes in maternal anxiety symptoms

    Anxiety symptoms will be measured using the Generalized Anxiety Disorder 7-Item Scale (GAD-7). The GAD-7 contains 7 items with a range of scores from 0 to 21. Higher scores indicate higher levels of anxiety symptoms.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  8. Changes in maternal Attention and Hyperactivity symptoms

    Changes in maternal ADHD symptoms will be measured using the Adult ADHD Self-Report Scale (ASRS). The ASRS is an 18-item questionnaire screening for ADHD symptoms in adults based on DSM criteria. Part A of the scale contains 6 items screening for the most predictive symptoms and Part B collects additional details. Total scores range from 0 to 72 with higher scores indicating greater frequency and severity of ADHD symptoms. All raw scores are converted into T-scores across all domains tested to have a standardized outcome.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  9. Measure of Child health

    Child health will be assessed using a parent-report questionnaire developed by the research team. Parents will be asked to respond to questions about their child's physical and mental health from birth to the present.

    Time frame: This measure will be administered at baseline (noted as T0), expected to occur sometime between weeks 0-1.

  10. Changes in harsh parenting

    Changes in harsh parenting will be measured using the Behaviour Assessment System for Children - Third Edition (BASC-3) Parenting Relationship Questionnaire. The BASC-3 is an 87-item parent-report questionnaire for children aged 2 to 18 years with 7 parenting behaviour subscales, including communication and involvement. Higher scores indicate more of the relevant subscale. Specifically, change in harsh parenting will be measured. All raw scores are converted into T-scores across all domains tested to have standardized outcomes.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

Other outcomes

  1. Changes in parent report measures of child executive function skills

    Changes in child executive function skills will be measured using the Behavior Rating Inventory of Executive Function - Second Edition (BRIEF-2). The BRIEF-2 is a 63-item parent-report questionnaire with 9 subscales, including inhibition, working memory, emotion control, and other clinically relevant subscales. Higher scores on each subscale indicate more of the relevant executive function skill. All raw scores are converted into T-scores across all domains tested to have standardized outcomes.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  2. Changes in academic achievement

    Changes in academic achievement will be measured using the Weschler Individual Achievement Test - Fourth Edition (WIAT-4). The WIAT-4 is an individually administered assessment for ages 4 to 50 measuring 4 key areas of academic achievement, including mathematics, reading, written expression, and oral language. Each of these areas contain several relevant subtests. Raw scores on the WIAT-4 are converted into both percentile ranks and composite subtest scores.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  3. Changes in knowledge, pattern recognition, and problem solving

    Changes in knowledge, pattern recognition, and problem solving will be measured using the Weschler Abbreviated Scale of Intelligence - Second Edition (WASI-II). The WASI-II is a standardized intelligence test for ages 6 to 90 with verbal and nonverbal subtests assessing various aspects of overall cognitive ability. All raw scores are converted into T-scores across all domains tested to have a standardized outcome.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  4. Changes in child core attention skills

    Changes in attention will be measured using the Continuous Performance Test - Third Edition (CPT-3). The CPT-3 is a computerized task measure for individuals aged 8 years or older assessing 4 key components, including inattention, sustained attention, impulsivity, and vigilance. During the task participants are instructed to respond to visual stimuli but ignore other visual stimuli. Performance is based on the number of commissions, omissions, perseverations, hit reaction time, detectability, and other factors.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  5. Changes in child inhibition skills

    Changes in inhibition will be measured using the Neurodevelopmental Assessment for Children - Second Edition (NEPSY-II). The inhibition subtest for ages 5 to 16 assesses impulse control and other components of executive functioning with scaled scores ranging from 1 to19. Higher scores on the inhibition subtest indicate greater response inhibition.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  6. Changes in maternal perceived social support

    Changes in maternal perceived social support from family, friends, and significant others will be measured using the Multidimensional Scale of Perceived Social Support. Total scores range from 12 to 84 with higher scores indicating higher levels of perceived social support.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  7. Service use

    Service use will be measured using a service use questionnaire developed by the research team. Participants will be asked questions regarding their interactions with police, child and family services, medical services, and community organizations during the past 1 year.

    Time frame: This measure will be administered at baseline (noted as T0), expected to occur before the beginning of the intervention

  8. Changes in maternal cannabis use

    Changes in maternal cannabis use will be measured using the Cannabis Use Disorder Identification Test (CUDIT). The CUDIT contains 8 items with a range of scores from 0 to 32. Higher scores indicate more hazardous cannabis use.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  9. Changes in maternal alcohol use

    Changes in maternal alcohol use will be measured using the Alcohol Use Disorder Identification Test (AUDIT). The AUDIT contains 10 items with a range of scores from 10 to 40. Higher scores indicate more hazardous or harmful alcohol use.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  10. Changes in recent Stressful Experiences

    The Recent Stressful Experiences (RSE) checklist was developed according to the recommendations of the JBP Research Network on Toxic Stress from the Center on the Developing Child at Harvard University. The RSE measures familial exposure to various stressors and contains 2 items that ask about stressors which participants may have experienced. Each of these items has a range of scores from 0 to 10 with higher scores indicating more stressful experiences. The RSE also contains 5 items measuring participants' ability to cope with stressful life events. Scores on these 5 items range from 4 to 21 with higher scores indicating a greater ability to cope with stress.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

  11. Changes in child affection recognition

    Changes in affect recognition will be measured using the Neurodevelopmental Assessment for Children - Second Edition (NEPSY-II). The affect recognition subtest assesses social perception with scaled scores ranging from 1 to 19. Higher scores on the affect recognition subtest indicate greater ability to identify and discriminate between emotions.

    Time frame: This measure will be administered at baseline (week 0-1; noted as T0) and after 10 weeks of BRIDGE intervention, post-intervention, which will occur between weeks 11-12 (noted as T1).

07

Study locations

1 site
08

References and documents

Publications

  • Theule, J., Wiener, J., Tannock, R., & Jenkins, J. M. (2010). Parenting stress in families of children with ADHD: A meta-analysis. Journal of Emotional and Behavioral Disorders, 21(1), 3-17. https://doi.org/10.1177/1063426610387433
  • Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W; SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019 Oct;144(4):e20192528. doi: 10.1542/peds.2019-2528. PubMed 31570648 ↗
  • Roos LE, Kaminski L, Stienwandt S, Hunter S, Giuliano R, Mota N, Katz LY, Zalewski M. The Building Regulation in Dual-Generations Program (BRIDGE): A Mixed-Methods Feasibility Pilot of a Parenting Program for Depressed Mothers of Preschoolers, Matched with Dialectical Behavior Therapy Skills. Child Psychiatry Hum Dev. 2023 Feb;54(1):34-50. doi: 10.1007/s10578-021-01219-1. Epub 2021 Aug 4. PubMed 34347227 ↗
  • Pinquart M. Associations of parenting dimensions and styles with externalizing problems of children and adolescents: An updated meta-analysis. Dev Psychol. 2017 May;53(5):873-932. doi: 10.1037/dev0000295. PubMed 28459276 ↗
  • Penner-Goeke L, Belows M, Kristjanson A, Andrade BF, Cameron EE, Giuliano R, Katz LY, Kelly LE, Letourneau N, Mota N, Reynolds K, Zalewski M, Pharazyn A, Roos LE. Protocol for a randomized control trial of the Building Regulation in Dual Generations Program (BRIDGE): preventing the intergenerational transmission of mental illness in at-risk preschool children. Trials. 2023 Sep 19;24(1):597. doi: 10.1186/s13063-023-07591-8. PubMed 37726821 ↗
  • Mingebach T, Kamp-Becker I, Christiansen H, Weber L. Meta-meta-analysis on the effectiveness of parent-based interventions for the treatment of child externalizing behavior problems. PLoS One. 2018 Sep 26;13(9):e0202855. doi: 10.1371/journal.pone.0202855. eCollection 2018. PubMed 30256794 ↗
  • Hong Y, Bertrand CM, Deater-Deckard K, Smith CL, Bell MA. The role of mother's and child's self-regulation on bidirectional links between harsh parenting and child externalizing problems. Dev Psychol. 2024 Mar;60(3):441-455. doi: 10.1037/dev0001661. Epub 2024 Jan 22. PubMed 38252104 ↗
  • Heard, H. L., & Linehan, M. M. (1994). Dialectical behavior therapy: An integrative approach to the treatment of borderline personality disorder. Journal of Psychotherapy Integration, 4(1), 55-82. https://doi.org/10.1037/h0101147

Individual participant data

Plan to share: Undecided — Given the sensitive nature of the data, we have not decided whether the data can be shared or not.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

Of 479 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 6 months is below that.

Counting every sponsor, half of 510 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2026
First posted
Nov 9, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07926776
Responsible party
Tasmia Hai (Assistant Professor, University of Manitoba) — Principal investigator
First posted
Nov 9, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Tasmia Hai, PhD
Contact
tasmia.hai@umanitoba.ca
14166609291

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion